Study on the Safety and Effectiveness of NUV-1511 for Adults with Advanced Solid Tumors

Inclusion Criteria

• Have advanced solid tumors, such as:
  • HER2-negative metastatic breast cancer that has worsened after certain treatments.
  • Metastatic castration-resistant prostate cancer (mCRPC) with specific prior treatments.
  • Pancreatic cancer that has progressed after chemotherapy.
  • Platinum-resistant high-grade serous ovarian, fallopian, or primary peritoneal cancer.
• Have measurable disease according to specific medical criteria.
• Have advanced solid tumors that have worsened after approved treatments or have no standard effective therapy available.
• Have adequate bone marrow and organ function.
• Be willing to provide informed consent and comply with study requirements.

Exclusion Criteria

• Have received chemotherapy, hormonal therapy, radiation, or biological anticancer therapy within 14 days before starting the study treatment.
• Have taken an investigational drug within 14 days before starting the study treatment.
• Have an ongoing or active infection requiring treatment or hospitalization within 2 weeks before starting the study treatment.
• Have a heart function below 50% as measured by specific tests.
• Have a history of significant heart disease or unstable heart conditions.
• Have an uncontrolled immunosuppressive disease or active autoimmune disease.
• Have had major surgery within 2 weeks before starting the study treatment or need major surgery during the study.
• Have another cancer within 2 years before starting the study treatment that could affect survival or tumor assessments.
• Be pregnant or breastfeeding.